Sybrava 284 mg Injection is a medicine containing Inclisiran as an active ingredient which belongs to the class of medications called proprotein convertase subtilisin kexin type-9 [PCSK-9]. It is first in class and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. It is used to lower the level of low density lipoprotein. It is prescribed as a complement to statin medication and diet in the management of patients with primary high cholesterol levels. It is not recommended to use this medication if you are allergic to the active compound Sybrava Injection or its components. It is not recommended to use during pregnancy and breastfeeding; it is advised to consult your physician regarding further queries. It is not recommended for children and adolescents under the age of 18. You should be taking a statin and following a diet to reduce your cholesterol before beginning this therapy. For the duration that you are receiving Sybrava 284 mg, you should continue taking the statin and adhering to this cholesterol-lowering diet. Do not stop taking this medicine without consulting your doctor. Talk to your doctor if you have kidney disorders, breathing problems, liver disorders, heart problems, or intolerance to sugars before taking this medicine. Inform your physician or pharmacist of any additional medications you are taking, have recently taken, or may take, including over-the-counter medications and herbal remedies.